Targeting specific immune cells to improve treatment for acute myeloid leukemia
Official title: Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
Funded at Beckman Research Institute/city of Hope · NIH-10890879 · Data updated 2026-11-12
This study is testing a new way to treat acute myeloid leukemia (AML) by using a special combination of targeted treatments that block a protein called STAT3 along with a type of radiation therapy, to see if it can help improve survival for patients whose cancer hasn't responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 19, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $687,979 |
| NIH project number | 5R01CA284593-02 |
| Project ID | NIH-10890879 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with treatment-refractory acute myeloid leukemia who are considering allogeneic hematopoietic cell transplantation.
✕Less likely to help
Patients with early-stage acute myeloid leukemia or those who are not candidates for allogeneic hematopoietic cell transplantation may not benefit from this research.
What this research studies
This research investigates a novel approach to treat acute myeloid leukemia (AML) by combining targeted oligonucleotide-based inhibitors of the STAT3 protein with a specialized radiation therapy called total marrow and lymphoid irradiation (TMLI). The goal is to enhance the effectiveness of TMLI, which has shown promise in improving survival rates for patients with treatment-refractory AML. By specifically inhibiting STAT3 in myeloid cells, the research aims to reduce the cancer-promoting effects of these cells and improve patient outcomes. Patients may be monitored for their response to this combined treatment strategy over the course of the study.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and reduce relapses in patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown that combining targeted therapies with radiation can improve outcomes in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Kortylewski, Marcin — Beckman Research Institute/city of Hope
- Study coordinator: Kortylewski, Marcin
Related research
Other NIH-funded projects on the same topics.
-
CD33-targeted immunotherapy to help AML patients
A patient-focused approach tests new antibody-drug strategies that target CD33 to improve safety and effectiveness for AML patients.
-
Myeloid-targeted oligonucleotide STAT3 blocker with TMLI for AML treatment
A new approach combines targeted radiation with a special gene-silencing treatment to help people with treatment-refractory acute myeloid leukemia.
-
Better CD33-targeted treatments for acute myeloid leukemia
Researchers are developing new CD33-targeted antibody therapies paired with a potent alpha-particle agent to help people with acute myeloid leukemia.
-
Improving treatment for acute myeloid leukemia with targeted radiation and immune therapy
This work explores a new way to treat acute myeloid leukemia that has been difficult to cure, by combining a special type of radiation with a targeted immune therapy.
-
Improving treatment for acute myeloid leukemia using targeted immunotherapy
This study is looking at new ways to make immunotherapy better and safer for people with acute myeloid leukemia (AML) by developing special antibodies that target a protein called CD33, and it aims to help improve treatment results while protecting healthy cells.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.